Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene autoleucel (YTB323) vs comparator in severe refractory idiopathic inflammatory myopathies
2024-514137-38-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Feb 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 24
01
Overview
Phase 2, randomised, open-label trial of rapcabtagene autoleucel in Autoimmune Myopathies (2 arms), sponsored by Novartis. Planned start Feb 2025; status: authorised.
02
Drugs
rapcabtagene autoleucel
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on 2024-514137-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514137-38-00.